These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16148605)

  • 1. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease.
    Testa A; Spoto B; Tripepi G; Mallamaci F; Malatino L; Fatuzzo P; Maas R; Boeger R; Zoccali C
    J Hypertens; 2005 Oct; 23(10):1825-30. PubMed ID: 16148605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease.
    Spoto B; Benedetto FA; Testa A; Tripepi G; Mallamaci F; Maas R; Boeger RH; Zoccali C; Parlongo RM; Pisano A
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1549-55. PubMed ID: 16364824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.
    Zoccali C; Bode-Böger S; Mallamaci F; Benedetto F; Tripepi G; Malatino L; Cataliotti A; Bellanuova I; Fermo I; Frölich J; Böger R
    Lancet; 2001 Dec 22-29; 358(9299):2113-7. PubMed ID: 11784625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
    Kielstein JT; Böger RH; Bode-Böger SM; Schäffer J; Barbey M; Koch KM; Frölich JC
    J Am Soc Nephrol; 1999 Mar; 10(3):594-600. PubMed ID: 10073610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease.
    Mallamaci F; Tripepi G; Maas R; Malatino L; Böger R; Zoccali C
    J Am Soc Nephrol; 2004 Feb; 15(2):435-41. PubMed ID: 14747391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study.
    Aucella F; Maas R; Vigilante M; Tripepi G; Schwedhelm E; Margaglione M; Gesualdo L; Boeger R; Zoccali C
    Atherosclerosis; 2009 Dec; 207(2):541-5. PubMed ID: 19501358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis.
    Guzik TJ; Black E; West NE; McDonald D; Ratnatunga C; Pillai R; Channon KM
    Am J Med Genet; 2001 Apr; 100(2):130-7. PubMed ID: 11298374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.
    Ravani P; Tripepi G; Malberti F; Testa S; Mallamaci F; Zoccali C
    J Am Soc Nephrol; 2005 Aug; 16(8):2449-55. PubMed ID: 15944335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between ENOS gene polymorphism and cardiovascular events in nondiabetic hemodialysis patients: a prospective study.
    Asakimori Y; Yorioka N; Tanaka J; Takasugi N; Harada S; Shigemoto K; Yamashita K; Usui K; Arita M; Kohno N
    Am J Kidney Dis; 2004 Jul; 44(1):112-20. PubMed ID: 15211444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease.
    Osanai T; Nakamura M; Sasaki S; Tomita H; Saitoh M; Osawa H; Yamabe H; Murakami S; Magota K; Okumura K
    Kidney Int; 2003 Dec; 64(6):2291-7. PubMed ID: 14633154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.
    Kanbay M; Afsar B; Siriopol D; Unal HU; Karaman M; Saglam M; Eyileten T; Gezer M; Verim S; Oguz Y; Vural A; Ortiz A; Johnson RJ; Covic A; Yilmaz MI
    Int Urol Nephrol; 2016 Jul; 48(7):1129-36. PubMed ID: 27007614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function.
    Leeson CP; Hingorani AD; Mullen MJ; Jeerooburkhan N; Kattenhorn M; Cole TJ; Muller DP; Lucas A; Humphries SE; Deanfield JE
    Circ Res; 2002 Jun; 90(11):1153-8. PubMed ID: 12065317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The missense Glu298Asp variant of the endothelial nitric oxide synthase gene is strongly associated with placental abruption.
    Yoshimura T; Yoshimura M; Tabata A; Yasue H; Okamura H
    Hum Genet; 2001 Mar; 108(3):181-3. PubMed ID: 11354626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.
    Zoccali C
    Blood Purif; 2002; 20(5):469-72. PubMed ID: 12207095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotid artery atherosclerosis in a population-based cohort.
    Karvonen J; Kauma H; Kervinen K; Rantala M; Ikäheimo M; Päivänsalo M; Savolainen MJ; Kesäniemi YA
    J Intern Med; 2002 Feb; 251(2):102-10. PubMed ID: 11905585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of eNOS Glu298Asp polymorphism with end-stage renal disease.
    Noiri E; Satoh H; Taguchi J; Brodsky SV; Nakao A; Ogawa Y; Nishijima S; Yokomizo T; Tokunaga K; Fujita T
    Hypertension; 2002 Oct; 40(4):535-40. PubMed ID: 12364359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arginine/asymmetric dimethylarginine ratio and cardiovascular risk factors in patients with predialytic chronic kidney disease.
    Hov GG; Sagen E; Hatlen G; Bigonah A; Åsberg A; Aasarød K
    Clin Biochem; 2011 Jun; 44(8-9):642-6. PubMed ID: 21406191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of nitric oxide synthase Glu298Asp polymorphism on the development of end-stage renal disease in type 2 diabetic Egyptian patients.
    El-Din Bessa SS; Hamdy SM
    Ren Fail; 2011; 33(9):878-84. PubMed ID: 21854353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and plasma concentrations of asymmetric dimethylarginine in Turkish pre-eclamptic women without fetal growth retardation.
    Turan F; Ilhan N; Kaman D; Ateş K; Kafkasli A
    J Obstet Gynaecol Res; 2010 Jun; 36(3):495-501. PubMed ID: 20598027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.